Adverse Effects of α-2 Adrenergic Agonists and Stimulants in Preschool-age Attention-deficit/Hyperactivity Disorder: A Developmental-Behavioral Pediatrics Research Network Study.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
06 2023
Historique:
received: 29 07 2022
revised: 16 12 2022
accepted: 11 01 2023
medline: 20 6 2023
pubmed: 18 1 2023
entrez: 17 1 2023
Statut: ppublish

Résumé

To characterize and compare the type and frequency of a range of common and uncommon adverse effects (AEs) associated with α-2 adrenergic agonist (A2A) and stimulant treatment of attention-deficit/hyperactivity disorder at preschool-age as well as to evaluate the impact of age on common AEs. This was a retrospective electronic medical record review of children <72 months of age (n = 497) evaluated at outpatient developmental-behavioral pediatric practices at 7 US academic medical centers within the Developmental-Behavioral Pediatrics Research Network. Data on AEs were abstracted for children who had treatment initiated by a developmental-behavioral pediatrician with an A2A or stimulant medication between January 2013 and July 2017; follow-up was complete by February 2019. A2A and stimulants had distinctive AE profiles. A2A compared with stimulants had a greater proportion with daytime sleepiness and headaches; stimulants had significantly greater proportions for most other AE, including moodiness/irritability, difficulty with sleep, appetite suppression, stomachaches, skin picking/repetitive behaviors, withdrawn behavior, and weight loss. Younger age was associated with disruptive behavior and difficulty with sleep. Stimulants had a greater rate of most AEs compared with A2A. AE profiles, together with efficacy, should inform clinical decision-making. Prospective randomized clinical trials are needed to fully compare efficacy and AE profiles of A2A and stimulants.

Identifiants

pubmed: 36649794
pii: S0022-3476(23)00021-5
doi: 10.1016/j.jpeds.2023.01.004
pii:
doi:

Substances chimiques

Central Nervous System Stimulants 0
Adrenergic Agonists 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

113325

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Irene M Loe (IM)

Department of Pediatrics, Stanford University, Stanford, CA. Electronic address: iloe@stanford.edu.

Nathan J Blum (NJ)

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA.

Justine Shults (J)

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA.

William Barbaresi (W)

Division of Developmental Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA.

Ami Bax (A)

Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

Jaclyn Cacia (J)

Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.

Alexis Deavenport-Saman (A)

Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA; Division of General Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.

Sandra Friedman (S)

Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.

Angela LaRosa (A)

Department of Pediatrics, Medical University of South Carolina, Charleston, SC.

Shruti Mittal (S)

Department of Pediatrics, Atrium Health, Concord, NC.

Douglas Vanderbilt (D)

Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA; Division of General Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.

Elizabeth Harstad (E)

Division of Developmental Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH